Hepatic steatosis cohort, repeat dose
TEAEs, pancreatitis
INJECTION SITE ERYTHEMA, HEPATIC STEATOSIS, PANCREATITIS
In participants with hepatic steatosis, 22 TEAEs were reported in 5 out of 6 (83.3%) participants receiving ARO-ANG3 compared to 8 TEAEs reported in all 3 (100%) participants receiving placebo (Extended Data Table There were no serious or severe TEAEs and no TEAEs leading to drug or study withdrawal in any participant receiving ARO-ANG3. One placebo participant experienced an SAE of moderate pancreatitis (Extended Data Table Two out of six (33.3%) participants reported TEAEs of injection site erythema that were deemed to be related to ARO-ANG3. In the placebo group, there were no TEAEs that were considered treatment related (Extended Data Table Waterfall plots show individual absolute changes in liver fat content, measured using MRI-PDFF at post-dose day 71 (Extended Data Fig. 